---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-080546"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:47:53.872938+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Olema Pharmaceuticals amends loan facility, ups potential borrowing to $100M, extends maturity to 2028

## Summary
- Borrowing capacity increased from $50M to up to $100M with $25M immediately available.
- Additional $25M available upon milestone: execution of first line pivotal Phase 3 trial of palazestrant with ribociclib.
- Further $50M may be available at bank's discretion; maturity extended 11 months to July 1, 2028.
- No funds drawn under the loan agreement to date.

## SEC filing metadata
- accession: 0000950170-24-080546
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017024080546/0000950170-24-080546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017024080546/olma-20240628.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-080546
- JSON: https://secwatch.observer/filing/0000950170-24-080546.json
- Plain text: https://secwatch.observer/filing/0000950170-24-080546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.